NCT02162303

Colchicine in Vascular Inflammation Assessed With PET Imaging

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Colchicine on Vascular Inflammation as Assessed With Position Emission Tomography (PET) Imaging in Patients With Atherosclerotic Vascular Disease (COLPET)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Montreal Heart Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to assess the effects of colchicine on vascular inflammation measured by (FDG)-PET imaging in patients with atherosclerotic vascular disease. This effect will also be measured by soluble plasma biomarkers. Finally, an optional pharmacogenomic investigation will be performed to identify genetic biomarkers of patient response.

Detailed description

This is an interventional trial targetting patients 18 years old or older with a carotid artery or an ascending aorta to background ration (TBR) of ≥1.6 as determined by 18 fluorodeoxyglucose (18F-FDG) uptake measured by positron emission tomography (PET) as evidence of atherosclerotic plaque inflammation. Following randomization,patients will be followed over a period of 6 months (24 weeks), through 2 phone contacts at 6 and 20 weeks and 2 on-site visits at 12 and 24 weeks. Each on-site visits will include blood draws to monitor routine chemistry and hematology,as well as biomarkers and lipid profiles. Each phone contacts will include monitoring of patient's general health and well-being. PET imaging will be performed at baseline and at the 24-weeks visit. Safety in this study will be assessed by clinical laboratory parameters, physical examinations, ECGs, vital signs, and the frequency and intensity of clinical adverse events (AEs). The Montreal Health Innovations Coordinating Center (MHICC) will be responsible for processing and quality control of the data. Project management will be carried out as described in the MHICC standard operating procedures (SOPs) for clinical studies. The handling of data, including data quality control, will comply with all applicable regulatory guidelines, MHICC SOPs and the study Data Management Plan. As such, a MHICC medical monitor will be appointed to the trial as the serious adverse event reporting contact (24/7).

Conditions

• Atherosclerotic Vascular Disease

Interventions

Type	Name	Description
DRUG	Colchicine	0.6 mg a day of active treatment or placebo for 24 weeks
DRUG	Placebo	Sugar,given once daily, over 6 months.To mimic active treatment

Timeline

• Start date: 2014-05-01
• Primary completion: 2015-07-01
• Completion: 2016-01-01
• First posted: 2014-06-12
• Last updated: 2020-02-21

Locations

1 site across 1 country: Canada